Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.37 |
| ▸ | SRC | P12931 | 4/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297705 | 0.91 | NPC1 (0.40) | PDE4BNPC1HPGDRAB9A | |
| SCHEMBL3948290 | 0.90 | ABCB1 (0.41) | ABCB1PRMT5SRC | |
| SCHEMBL7862914 | 0.90 | ABCB1 (0.41) | ABCB1PRMT5SRC | |
| SCHEMBL30207112 | 0.85 | ABCB1 (0.47) | ABCB1PRMT5SRCGPR119MCL1 | |
| SCHEMBL4292542 | 0.85 | ABCB1 (0.47) | ABCB1PRMT5SRCGPR119MCL1 | |
| SCHEMBL13663655 | 0.83 | PDE4B (0.42) | PDE4BNPC1HPGDRAB9ASRC | |
| SCHEMBL8064347 | 0.83 | PDE4B (0.42) | PDE4BNPC1HPGDRAB9ASRC | |
| SCHEMBL3945721 | 0.82 | PDE4B (0.42) | PDE4BNPC1HPGDRAB9ASRC | |
| SCHEMBL13662025 | 0.82 | NPC1 (0.34) | NPC1HPGDRAB9A | |
| SCHEMBL3955172 | 0.82 | HDAC8 (0.38) | ABCB1GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | ABCB1 632/4885PDE4B 1929/4885NPC1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.